Tabei Tadashi, Natsume Ichiro, Kobayashi Kazuki
Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan.
Department of Respiratory Medicine, Yokosuka Kyosai Hospital, Yokosuka, Kanagawa, Japan.
Int J Urol. 2017 Sep;24(9):708-710. doi: 10.1111/iju.13420. Epub 2017 Jul 21.
The efficacy and safety of nivolumab for patients receiving dialysis treatment has not been established yet. Herein, we describe a patient on dialysis successfully treated with nivolumab as seventh-line therapy for metastatic renal cell carcinoma. Before initiating nivolumab, he had respiratory discomfort induced by a lesion occluding the left intermediate bronchus that originated from the metastatic lymph node behind the tracheal bifurcation. Four weeks after nivolumab was initiated, his symptom remarkably improved, and the occlusion disappeared according to the bronchoscopy examination. The effectiveness and safety of nivolumab has continued for 6 months. There are few cases in which nivolumab has been given to patients on dialysis. In the present case, nivolumab was given to a patient on dialysis, and it resulted in a remarkable improvement without any adverse events.
纳武单抗用于接受透析治疗患者的疗效和安全性尚未确立。在此，我们描述了一名接受透析的患者，其作为转移性肾细胞癌的七线治疗成功接受了纳武单抗治疗。在开始使用纳武单抗之前，他因起源于气管分叉后转移性淋巴结的病变阻塞左中间支气管而出现呼吸不适。开始使用纳武单抗四周后，他的症状显著改善，并且根据支气管镜检查，阻塞消失。纳武单抗的有效性和安全性持续了6个月。给透析患者使用纳武单抗的病例很少。在本病例中，给一名接受透析的患者使用了纳武单抗，结果症状显著改善且未出现任何不良事件。
